Background-PKD2-related autosomal dominant polycystic kidney disease (ADPKD) is widely acknowledged to be of milder severity than PKD1-related disease, but population-based studies depicting the exact burden of the disease are lacking. We aimed to revisit PKD2 prevalence,
Autosomal dominant polycystic kidney disease (ADPKD) is the most widespread monogenic kidney disorder worldwide. Its precise prevalence is difficult to assess, and although the theoretical lifetime risk for ADPKD has been estimated at about 10/10,000, 1 minimum point prevalences of 2.9 and 3.3/10,000 were determined in 2 population-based studies conducted in the United Kingdom and Germany, respectively. [2] [3] [4] PKD1 (MIM [Mendelian Inheritance in Man] 601313, located on chromosome 16p13.3) 5 and PKD2
(MIM 173910, located on chromosome 4q21) 6 are the principal genes known to cause ADPKD, with an overall mutation detection rate of ~90%. 7, 8 A third gene, GANAB, has recently been described in 9 pedigrees, causing milder polycystic kidney disease, but in some cases severe polycystic liver disease. 9 Mutations to PKD1 account for the disease in 80% to 85% of mutation-positive pedigrees, whereas PKD2 mutations are identified in the remaining 15% to 20%. 8, [10] [11] [12] [13] A recent study suggested a higher contribution of PKD2 mutations in ADPKD, ~30%, but the cohort was enriched in patients with milder disease. 14 PKD1 encodes polycystin 1 (PC1), a multidomain glycoprotein of 4,303 amino acids that is cleaved at a G protein-coupled receptor proteolytic site. Polycystin 2 (PC2), a 968-aminoacid protein, is encoded by PKD2 and belongs to the transient receptor potential family of calcium-regulated cation channels. The cytoplasmic carboxy-terminal coiled-coil domain of PC1 is known to interact with PC2; this interaction is determinant for PC1 maturation, trafficking to the cilia, and stability. 15, 16 Although there is considerable phenotype overlap between PKD1-and PKD2-related ADPKD, typically the latter appears to be a much less severe disorder, with end-stage renal disease (ESRD) being less frequent and occurring later in life, as underlined by the respective median ages at ESRD: about 55.6 years for truncating variants of PKD1, about 67.9 years for nontruncating mutations of PKD1, and about 79.7 years for PKD2. 11 In contrast, the severity of polycystic liver disease seems similar in patients with PKD1 and PKD2 mutations. 17 Considerable progress in understanding pathways involved in cystogenesis has been made in the past few years [18] [19] [20] and allowed the current development of specific therapies. 21, 22 In this context, accurate description of the ADPKD phenotype is important and represents a key step to delineate which patients should receive these new treatments. Since the discovery of both genes about 20 years ago, several studies have reported the ADPKD phenotypic spectrum, but only a few studies have focused on the population with PKD2 mutations. [23] [24] [25] For those studies, PKD2 involvement was assessed mainly by linkage, and as a result, the cohorts consisted mainly of large pedigrees collected through international collaborations. Hence, small families and sporadic cases were under-represented. Another unaddressed question remains the true prevalence of PKD2-related ADPKD, which is difficult to evaluate given the proportion of individuals with PKD2 mutations that remain undiagnosed until late adulthood.
Genkyst is an ongoing observational cohort, the aim of which is to include all patients with ADPKD followed up in the nephrology centers of western France, irrespective of disease severity. 11, 12 Through this population-based study, we aimed to describe the clinical presentation of PKD2-related ADPKD and investigate factors affecting progression to chronic kidney disease (CKD). In addition, we explored the prevalence of PKD2 mutations using publicly available whole-exome sequencing data and have provided, we believe for the first time, an estimate of the genetic prevalence of ADPKD.
METHODS

Patients
This study is a cross-sectional study of the Genkyst cohort, resulting from the collaboration of 22 nephrology centers in western France. 11, 12 Patients with ADPKD were recruited in January 2010 to March 2016. In individuals with a positive familial history, diagnosis of ADPKD was based on the Pei criteria: that is, at least 3 renal cysts before the age of 39 years, at least 2 cysts per kidney from age 40 to 59 years, and at least 4 cysts per kidney after the age of 60 years. 26 In the absence of familial history, diagnosis required the presence of at least 10 bilateral kidney cysts. The patients' clinical data obtained during medical interviews at the time of their inclusion and from medical records were entered in a standardized clinical report form. All participants provided informed consent, and the local ethics committee approved the study (CCTIRS 10.385).
Molecular Analysis
The entire coding regions of the PKD1 and PKD2 genes and their flanking intronic regions were screened by Sanger sequencing, as previously described. 7 Patients with no clear pathogenic mutation detected after Sanger sequencing were screened for gross rearrangements using multiplex ligation-dependent probe amplification and array-based comparative genomic hybridization. Mutations were classified as truncating (frameshifting, indels, nonsense mutations, canonical splicing changes, and in-frame indels ≥ 5 amino acids) or nontruncating (missense, in-frame indel ≤ 4 amino acids, noncanonical splicing events, and non-stop mutations).
Prevalence Calculation
Brittany is a well-defined geographic area of 3.258 million inhabitants. 27 The prevalence of patients with PKD2 mutations in Brittany followed up in nephrology centers was calculated at the midpoint of the study, March 31, 2013 , as the number of patients alive at that date divided by the number of inhabitants in Brittany on January 1, 2013, closest census point. The 95% confidence intervals (CIs) for prevalence rates were computed assuming that the observed number of cases follows a Poisson distribution.
Because a significant number of patients with PKD2 mutations may not be diagnosed or referred to a nephrology center, we estimated the genetic prevalence of PKD2. The Exome Aggregation Consortium (ExAC, Cambridge, MA) is a collection of exome data of 60,706 unrelated and ostensibly healthy individuals from different origins. 28 ExAC data were downloaded from http://exac.broadinstitute.org and analyzed using SNP & Variation Suit, version 7 (Golden Helix). Truncating variants (nonsense, splice, and frameshift mutations) and missense variants known to be fully penetrant were inventoried, with their respective allele counts, and entered in the calculation of the genetic prevalence. In order to confirm the results obtained by this first calculation, we also considered nonsense and splice mutations alone and evaluated the total number of pathogenic mutations by adjusting our count to the proportion of nonsense and splice mutations in all PKD2 single pedigrees reported in the Mayo ADPKD mutation database. 29 
Statistical Analysis
Overview-All statistical analyses were performed using SPSS software, version 19 (IBM Corp), and JMP Pro, version 11.2.1 (SAS Institute Inc). Median values were compared using a nonparametric Mann-Whitney test or Kruskal-Wallis test, depending on the number of groups.
Analysis of Predictors of Kidney Function-Effects of sex, smoking status, number of pregnancies, mutation type, and mutation position on kidney function were individually analyzed using a linear regression taking age into account. A square-root transformation of estimated glomerular filtration rate (eGFR, calculated using CKD-EPI [CKD Epidemiology Collaboration] creatinine equation 30 ) was performed to comply with the normality required by this analysis. All variables significantly associated with age-adjusted square-roottransformed eGFR at a threshold of 0.2 were then entered in a multivariable linear regression. In order to also include patients having reached ESRD in these analyses, the last eGFR before initiating renal replacement therapy and the corresponding age were taken into account for patients with ESRD. To quantify the degree to which individuals belonging to the same pedigree or sharing the same mutation correlate with each other in regard to eGFR, we determined the intraclass correlation coefficient, adjusting for age and sex.
Analysis of Renal Survival-Renal survival (time from birth to ESRD) and hypertension-free survival (time from birth to diagnosis of hypertension) were analyzed using the Kaplan-Meier method. Differences between survival curves in male and female patients were assessed using a log rank test with a 0.05 significance level.
RESULTS
Patient Characteristics and Description of Mutation Spectrum
A PKD2 mutation was identified in 293 patients from 203 pedigrees. PKD2 pedigrees represented 20.2% of the 1,006 mutation-positive pedigrees registered in the Genkyst cohort as of March 2016. Characteristics of patients at inclusion are presented in Table 1 . A total of 83 different mutations were reported in the 203 pedigrees (Table S1 , available as online supplementary material). These mutations spanned the entire coding region of the PKD2 gene (Fig 1) and were mainly truncating mutations (87.7% of mutations, 85.7% of pedigrees; Table S2 ).
Prevalence of PKD2-Related ADPKD
A majority of the patients with PKD2 mutations (n = 207; 149 pedigrees) live in Brittany (a well-defined geographic area of 3.258 million inhabitants 27 ), reflecting the early involvement of these centers in the study. At the midpoint of the study period, 204 patients were alive, and the number of patients with PKD2 mutations in Brittany included in the Genkyst cohort was hence calculated at 0.63 (95% CI, 0.54-0.72)/10,000. However, because only a fraction of patients with PKD2 mutations are likely to be seen in these centers, we compared these numbers with PKD2 mutations detected in the ExAC database. A total of 11 fully penetrant variants were identified in 14 patients (Table S3) . Thus, PKD2 genetic prevalence was estimated at 2.31 (95% CI, 1.10-3.51)/10,000 in the whole ExAC population. Because some deletion or insertion mutations reported in ExAC may represent false positives due to misalignment of the exome sequences, we verified the consistency of our results taking into account only nonsense and typical splice mutations, which correspond to 60% of the pathogenic mutations reported in the 438 unique pedigrees of the ADPKD mutation database. 29 Considering that 8 individuals were found to have a splice or nonsense variant, we calculated that about 13.3 patients would have a mutation of PKD2, hence a prevalence of 2.19 (95% CI, 1.01-3.37)/10,000, consistent with our initial value. Because the ExAC database comprises patients with different ethnicities, we also considered separately the European population (n = 36,677), in which 6 individuals were found to have a PKD2 mutation, corresponding to a prevalence of 1.64 (95% CI, 0.33-2.94)/ 10,000.
Diagnosis and Clinical Features of ADPKD in PKD2 Patients
Diagnosis of ADPKD-Median age at diagnosis was 42 (range, 9-84.5) years (n = 262), and the diagnosis was made significantly earlier in women (median age at diagnosis, 40 vs 47 years; P < 0.001). ADPKD was diagnosed incidentally during an abdominal imaging examination prescribed for another indication in 95 (32.5%) patients, due to a familial study in 71 (24.3%), following a urologic complication in 65 (22.3%), and for exploring secondary hypertension in 31 (10.6%; Fig 2) . Exact eGFRs at diagnosis were available for a minority of patients, but analysis of past eGFR values when available (n = 226) showed that 81.4% of patients had eGFRs > 60 mL/min/1.73 m 2 at diagnosis. 3A) .
Hypertension-Hypertension
Urologic Events-Urologic events, including flank pain related to cysts, macroscopic hematuria or symptomatic intra-cystic hemorrhage, cyst infections, and kidney stones, were reported by 175 (59.7%) patients (see Table 2 for prevalence and median age at first occurrence). Cumulative probabilities of having had at least one of these complications were 54.6% (95% CI, 47.5%-61.7%), 60.4% (95% CI, 53.3%-67.5%), and 63.8% (95 CI%, 56.3%-71.3%) at age 60, 65, and 70 years, respectively. There was no significant difference between men and women.
Kidney Function and Factors Influencing Kidney Function
Distribution of patients according to CKD stage is reported in To assess the influence of clinical and genetic factors on kidney function, we performed univariate and multivariate linear regressions. Male sex was associated with lower eGFRs (negative β value in Table 3 ), which is illustrated in Fig 3C. There was no influence of smoking status on eGFRs after multivariate analysis, and number of pregnancies was not associated with kidney function (Table 3) . Truncating mutations were associated with lower age-adjusted eGFRs (negative β value in Table 3 and Fig 3D) , and mutation position did not influence kidney function. Intrafamilial correlation analysis estimated that belonging to the same pedigree explained 34.1% of the variability in eGFRs, while sharing the same PKD2 mutation explained only 7.1% of the variability in eGFRs. Last, we focused on a subgroup of 18 patients presenting with more severe renal involvement, defined by ESRD onset before the age of 60 years. In this subgroup, 8 patients had at least one severe associated condition or nephropathy likely to account for early progression to ESRD (listed in Table 4 ).
DISCUSSION
We report a detailed clinical presentation of PKD2-related ADPKD through a populationbased study in a cohort of 293 patients from western France.
In France, most patients with ADPKD are referred to a nephrologist at an early stage of the disease. The Genkyst cohort involves all nephrologists of a single area and aims to include all consenting patients with ADPKD, irrespective of CKD stage, and is in this regard very representative of disease severity. PKD2 represents 20% of the mutation-positive pedigrees of the Genkyst cohort, which is a little higher than previously reported 7, 8 and yet probably underestimates its true prevalence. Consistent with that point, PKD2 genetic prevalence in Europe of 1.64/10,000, derived from the analysis of ExAC data, is almost 3 times higher than the number of the cases followed up in nephrology centers. The difference is likely due to younger individuals who are undiagnosed and patients with mild disease not followed up at a nephrology center or who remain undiagnosed in adulthood.
Use of an ExAC data set is an original way to address the much-debated question of ADPKD prevalence. Because two-thirds of PKD1 sequence is duplicated on 6 pseudogenes, analysis of this gene region by exome capture and next-generation sequencing is not reliable. However, if we consider that patients with PKD2 mutations represent at most about 20% to 30% of the total patients with ADPKD [12] [13] [14] and that PKD2 prevalence in Europe is about 1.6/10,000 (or 1/6,112), an overall prevalence of individuals with PKD1 or PKD2 mutation would be between 5.45 and 8.18/10,000 (or 1/1,222 and 1/1,833). This figure is consistent with estimates of lifetime prevalence of ADPKD 1,31,32 and higher than ADPKD pointprevalence estimates. [2] [3] [4] Because the ExAC data set includes a majority of ostensibly healthy individuals, this genetic prevalence is more likely to be under-than overestimated because some patients with PKD2 mutations may not be included. 28 In addition, although some missense variants of PKD2 identified in ExAC may be pathogenic, they were not included given the lack of information on their functional consequences, which could lead to another underestimation bias.
In this study, we identified a significant number of recurrent mutations. Despite careful reanalysis of the pedigrees and discussion with patients, we were not able to link the families sharing the same mutation, but the presence of founder effect is likely for some of the mutations identified.
Taking this cohort into consideration, we can summarize the PKD2-related disease presentation in 3 ways. First, despite often having a positive family history, a diagnosis of PKD2-related ADPKD is typically made late, usually after the fourth decade. Familial investigation accounted for the diagnosis in <25% of cases and ADPKD was more often diagnosed incidentally during radiologic examination or following urologic events. Second, although a mild disease, PKD2-related ADPKD is far from being asymptomatic, as illustrated by the high prevalence of urologic events, with almost 40% of patients reporting flank pain, ~30% reporting macroscopic hematuria or cyst hemorrhage, and a cumulative probability of having presented with at least 1 urologic event >60% at the age of 70 years. Corresponding figures traditionally reported in the literature for the overall ADPKD population are slightly higher, with 60% of the adult population reporting flank pain and the same proportion reporting macroscopic hematuria or cyst hemorrhage. 10, 33 Hypertension was also highly penetrant, with a cumulative probability of hypertension at the age of 70 years >90%, which implies that blood pressure should be carefully monitored in at-risk individuals. As expected, median age at diagnosis of hypertension was 10 years later than reported in patients with PKD1-related disease. 11 Third, CKD progression is slow in the great majority of cases. Unlike a previous study, 6 we did not identify a sex influence on renal survival in patients with PKD2 mutations, probably due to the low number of them reaching ESRD, which makes group comparisons difficult. However, male patients had significantly lower eGFRs than female patients, in agreement with a recent report. 13 The overall consistency of the PKD2-related disease presentation reinforces the importance of molecular genetics in the prognostic assessment of patients with ADPKD, especially at an early stage of the disease when cyst burden is still limited. Because disease severity varies in patients with PKD2 mutations, genetic information should be considered along with clinical information, such as age at diagnosis of hypertension and age at first urologic event, using the PROPKD [Predicting Renal Outcome in Polycystic Kidney Disease] score 12 to provide prognostic information at an individual level. With the current widespread use of nextgeneration sequencing, the cost of molecular analysis is expected to decrease constantly. [34] [35] [36] [37] [38] Interestingly, mutation type significantly influenced eGFR in our multivariable linear regression, with truncating mutations associated with lower eGFRs. Given the small number of patients with nontruncating mutations (n = 36), this information should still be considered with caution. It is likely that some of the nontruncating mutations identified may correspond to hypomorphic variants. For instance, the mutation p.R322W (substitution of a tryptophan for an arginine at amino acid 322), identified in 5 patients of the cohort, has been shown to cause a significant decrease in the level of mature PC1 in vitro, but this level is still higher than in the presence of PKD2 truncating mutation. 16 This may be the case for a majority of the missense variants identified here, accounting for the apparent milder nature of the disease within this group. However, the mutation p.R322Q (substitution of a glutamine for an arginine at amino acid 322), identified in 3 patients, completely prevents PC1 maturation and surface/ciliary localization. 16 In order to refine genotype-phenotype correlations within patients with PKD2 mutations, a systematic in vitro assessment of each missense variant identified will have to be undertaken. Beyond allelic influence, additional modifier genes are probably modulating the severity of the kidney disease. This is supported because the correlation of individuals belonging to the same pedigree explained 34.1% of the variability in eGFRs, whereas the correlation of individuals sharing the same mutation explained only 7.1% of this variability.
The vasopressin 2 receptor antagonist tolvaptan is available in Canada and Japan and recently gained marketing authorizations in Europe. Several other promising therapeutic agents are currently under evaluation. 21 The existence of these new therapeutic options will probably cause patients with ADPKD to be referred to nephrology centers more frequently and earlier in the course of the disease than presently. One burning question arises: should all patients with ADPKD be considered for those new therapies? This study shows that in patients with PKD2 mutations, risks for reaching ESRD are 9.8% and 18.5% at the ages of 60 and 65 years, respectively. Furthermore, in almost half the patients who reached ESRD before age 60 years, a concomitant nephropathy was identified, and the absence of massive enlargement of the kidneys was suggestive of a predominant role of these cofactors in the development of kidney failure. A position statement for the use of tolvaptan in ADPKD has recently been issued by a European group of experts. 39 These recommendations suggest limiting tolvaptan use to adult patients aged 18 to 30 years with CKD stages 1 to 3a, aged 30 to 40 years with CKD stages 2 to 3a, and aged 40 to 50 years with CKD stage 3a who, in addition, have an eGFR decline or kidney growth suggestive of rapidly progressing disorder. In our PKD2 cohort, only 25 patients, including 12 patients younger than 30 years, had a CKD stage and age class matching these criteria. Considering the later loss of kidney function in patients with PKD2 mutations, the tolerance profile, and the cost of tolvaptan, it seems presently difficult to advocate for the early initiation of a long-term treatment. However, some specific situations, such as a familial history of early-onset ESRD, should raise awareness and lead to careful and regular clinical reevaluation.
This study has some limitations. Because PKD2-related ADPKD is probably underdiagnosed, the description of its clinical course does not reflect all individuals harboring PKD2 mutations, but only patients who have been diagnosed. Younger patients and patients presenting with milder forms of PKD2-related disease may not be diagnosed or referred to nephrology centers.
In conclusion, although PKD2-related ADPKD is typically milder than PKD1-related ADPKD, it should not be considered asymptomatic. Earlier referral and careful familial investigations may enable nephrologists to provide timely symptomatic care and educate patients about a healthy lifestyle, which may reduce environmental modulations of the phenotype. The extent to which patients with PKD2 mutations should receive new targeted therapies presently remains uncertain.
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Refer to Web version on PubMed Central for supplementary material. Context of diagnosis in PKD2 patients. Table 3 Effect of Clinical and Genetic Variables on Age-Adjusted Square-Root-Transformed eGFR Note: Early-onset ESRD defined as before age 60 years. Kidney sizes at ESRD are reported when available and were measured prior to initiation of renal replacement therapy.
Abbreviations: ESRD, end-stage renal disease; L, left; ND, not documented; R, right.
a Mutations designated at the protein level (p) or coding DNA level (c). For protein-level mutations, R is arginine, X is a premature stop codon, E is glutamate, and K is lysine. For coding DNA-level mutations, del indicates deletion, whereas dup denotes duplication.
